US-based firm Domus Diagnostics is ready to start clinical testing of its Covid-19 testing platform prototype.

The new SARS-COV-2 diagnostic test is designed to address the global need for accessible and rapid nucleic acid amplification tests (NAATs).

It is based on reverse transcription loop-mediated isothermal amplification (RT-LAMP) technology and aims to provide user-friendly, affordable and accurate infectious disease detection.

Domus will initially submit the test for approval through the World Health Organization (WHO). It will then be able to provide the test to governments and public health organisations in developing countries.

Upon completion of clinical trials, the company plans to also seek authorisation from the US Food and Drug Administration (FDA) for a multiplex test for Covid-19 and seasonal flu, as the Domus platform has the ability to detect multiple disease targets from a single sample.

To perform the test, individuals collect a nasal swab sample from each nostril and insert a collection chamber into a card. The results are obtained in 30 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Domus Diagnostics president and CEO Paul Chapman said: “Inequities in vaccine and testing availability are one of the main reasons that we see significant disparities in outcomes between countries and between people of different racial and ethnic backgrounds.

“Domus’ vision is to provide a simple to use, highly accurate test that can be produced affordably at scale.

“Our talented team of scientists and engineers have developed a truly innovative NAAT testing solution that can finally address those testing gaps that have existed for decades between the developing world and the West.”

The company stated that the test can achieve accuracy equivalent to a PCR test and does not require instrumentation, electricity or cold chain logistics.